Tuesday, September 12, 2023
Pre-Workshop: Fundamentals of Global Cancer Drug Development
8:50 AM(EST)
OPENING OF PRE WORKSHOP EDUCATIONAL SESSION
AAADV Program Committee: H. Kim Lyerly (Duke University)
9:00 AM(EST)
Plenary Session A: Overcoming the hazards of survival analysis - PFS, RFS, HR, RMST, and CSO
Session Chairperson: Martin Stockler (University of Sydney)
- Martin Stockeler (University of Sydney) Time to event analysis in oncology
- Elizabeth Eisenhauer (Queens University) Progression-free survival in advanced cancer
- Ian Tannock (University of Toronto) Relapse-free survival and adjuvant therapy
- Ludovic Trinquart (Tufts Univeristy) Use and abuse of hazard ratios in oncology
- Mahesh (Max) Parmar, (MRC CTU UCL) Restricted mean survival time in oncology
- Bishal Gyawali (Queens, Kingston, ON) Time for Common Sense in Oncology
- Panel Discussion
12:00 PM(EST)
Break
![Thomas Fleming, PhD](https://aaadv.org/wp-content/uploads/2019/05/Tom-Fleming-Ph.D..png)
![](https://aaadv.org/wp-content/uploads/2023/09/McShaneL_portrait_for_biosketch-768x1024.jpg)
![](https://aaadv.org/wp-content/uploads/2023/07/John-H.-Powers-III.jpg)
![](https://aaadv.org/wp-content/uploads/2023/09/dueck_headshot.jpg)
12:30 PM(EST)
Plenary Session B: STATISTICAL DESIGN AND ANALYSIS
Session Chairpersons: Thomas Fleming (University of Washington, Seattle) and Lisa McShane (National Cancer Institute)
- Thomas Fleming (University of Washington, Seattle) Subset analysis
- John H. Powers (George Washington University) Surrogate biomarkers/endpoints
- Amylou C. Dueck (Mayo Clinic) Patient reported outcomes for assessing benefits & harms in cancer treatment and prevention trials.
- Panel Discussion
3:30 PM(EST)
END
Wednesday, September 13, 2023
![](https://aaadv.org/wp-content/uploads/2019/05/Gwen-Nichols-M.D..png)
![Eric Klein](https://aaadv.org/wp-content/uploads/2023/09/Screenshot-2023-09-06-at-12.20.54-PM.png)
![](https://aaadv.org/wp-content/uploads/2023/07/Irene-Ghobrial-MD-e1693411593461.jpg)
![](https://aaadv.org/wp-content/uploads/2023/07/Lachelle-D.-Weeks-MD-PhD.jpg)
![](https://aaadv.org/wp-content/uploads/2023/07/Jacques-Mascaro.jpg)
![](https://aaadv.org/wp-content/uploads/2023/07/Jeff-Venstorm-e1693410846739.jpg)
9:00am (EST)
Plenary Session #1: Detecting cancer precursors: The changing landscape of early detection of cancer/cancer precursors
Session Chairperson: Gwen Nichols, (Leukemia and Lymphoma Society)
- Gwen Nichols (Leukemia & Lymphoma Society) Introduction
- Eric Klein (GRAIL) Multicancer early detection diagnostic tests (MCED)
- Lachelle Weeks (Dana Farber Cancer Institute) Science and testing possibilities for clonal hematopoiesis of indeterminate potential (CHIP)
- Irene Ghobrial (Dana Farber Cancer Institute) Early natural history of myeloma: from MGUS on
- Jacques Mascaro (AstraZeneca) Regulatory challenges in early detection and prevention of cancer
- Panel Discussion
- Jeffrey Venstrom (GRAIL) Invited discussant
11:00am (EST)
Plenary Session #2: The utility and success of multi-center basket trials in cancer drug development:
Session Chairperson: Richard Schilsky (University of Chicago)
- Rich Schilsky (University of Chicago): Targeted Agent and Profiling Utilization Registry (TAPUR)
- Emile E. Voest (Netherlands Cancer Institute): Netherlands Drug Rediscovery Protocol (DRUP)
- Janet Dancey (Canadian Clinical Trials Group): Canadian Profling and Targeted Agent Utilization Trial (CAPTUR)
- Panel Discussion
- Scott Patterson (Gilead) Invited Discussant
- Tania Szado (Genetech) Invited Discussant
- Deo Ruhangaza (Butaro Cancer Center, Rwanda) Invited Discussant
1:00pm (EST) Wednesday, September 13
Break
1:30pm (EST)
Plenary Session #3: The development of precision medicine in LMIC:
Session Chairpersons: Bob Li, (Memorial Sloan Kettering Cancer Center), Katherine Van Loon (UCSF)
- Aminu Umar-Sadiq (Nigeria Sovereign Investment Authority) Investing in Cancer Centers of Excellence in Nigeria (NLCC)
- Jennifer Dent (BioVentures) The Cancer Clinical Trial Landscape in Africa and through AC3T
- Abasi Ene-Obong (Syndicate Bio) Genomic testing in LMIC
- Panel Discussion
- Chitkala Kalidas (Bayer) Invited Discussant
- Adedayo Joseph (NLCC) Invited Discussant
3:30pm (EST) Wednesday, September 13
End
Thursday, September 14th, 2023
9:00am (EST)
Keynote: The White House Cancer Moonshot
![](https://aaadv.org/wp-content/uploads/2023/07/Philip-E.-Castle-Ph.D.-M.P.H-e1689796578274.jpg)
9:25am (EST)
Discussion- Cancer Prevention Opportunities in 2023
![](https://aaadv.org/wp-content/uploads/2023/07/Philip-E.-Castle-Ph.D.-M.P.H-e1689796578274.jpg)
![](https://aaadv.org/wp-content/uploads/2023/07/Ludmil-Alexandrov-e1689796779266.jpg)
![](https://aaadv.org/wp-content/uploads/2023/07/Sudhir-Srivastava-Ph.D.-M.P.H-e1689796878838.jpg)
![Mary "Nora" Disis](https://aaadv.org/wp-content/uploads/2023/09/Screenshot-2023-09-12-at-9.53.52-PM.png)
10:00am (EST)
Plenary Session #3: Carcinogenesis and the emerging science of precision prevention
Session Chairperson: Philip E. Castle (Divison of Cancer Prevention, National Cancer Institute (DCP-NCI)
- Ludmil Alexandrov (University of California, San Diego): The genomic landscape of human precancer
- Sudhir Srivastava (National Cancer Institute): The Biology of Precancer
- Mary “Nora” Disis (University of Washington, Seattle): Immunoprevention
- Panel Discussion
![](https://aaadv.org/wp-content/uploads/2022/07/Dr.SusanGalbra001-scaled-e1658986993152.jpg)
12:00pm (EST)
Keynote: Drug development for cancer prevention: opportunities and challenges.
- Introduction: H. Kim Lyerly (Duke University)
- Speaker: Dr. Susan Galbraith (AstraZenca)
- Discussion
12:30pm (EST)
Plenary Session #5: Case studies in cancer prevention Successes and pitfalls
Session Chairperson: Renzo Canetta (Independent Consultant)
- John Schiller (National Cancer Institute): HPV vaccines for cervical and other cancers
- David M. Miller (Harvard University): Nicotinamide for skin cancer after transplant
- Seema Khan (Northwestern University): Tamoxifen for breast cancer
- Andrew Chan (Harvard University): Celecoxib and Aspirin For colorectal adenomatous polyps
- Ian Thompson (National Cancer Institute): Dutasteride/finasteride for prostate cancer prevention
- Panel Discussion
2:30pm (EST)
Plenary Session #6: Regulatory pathways for next generation prevention agents:
Session Chairperson: Robert H. Shoemaker (National Cancer Institute, Divison of Cancer Prevention)
- Steven Reed (HDT Bio): mRNA vaccines in cancer prevention
- Zelanna Goldberg (Replicate Bioscience): Self replicating mRNA vaccines preventing resistance
- Brian Cholewa (National Cancer Institute, Divison of Cancer Prevention): Regulatory pathways
- Shizuko Sei (National Cancer Institute, Divison of Cancer Prevention): NCI-DCP activities in cancer prevention
- Panel Discussion
4:30pm (EST) Thursday, September 14
End
Friday, September 15th, 2023
![](https://aaadv.org/wp-content/uploads/2023/09/McShaneL_portrait_for_biosketch-scaled.jpg)
![](https://aaadv.org/wp-content/uploads/2023/07/Screenshot-2023-07-29-at-1.20.28-PM.png)
![](https://aaadv.org/wp-content/uploads/2023/07/Screenshot-2023-07-29-at-1.21.59-PM.png)
![](https://aaadv.org/wp-content/uploads/2023/07/Screenshot-2023-07-29-at-1.18.53-PM.png)
![](https://aaadv.org/wp-content/uploads/2023/09/Screenshot-2023-09-12-at-9.49.40-PM.png)
9:00am (EST)
Satellite #4: Clinical trial design/analysis for global drug development
Session Chairperson: Lisa McShane (National Cancer Institute)
- Lisa McShane (National Cancer Institute): Clinical trial designs to evaluate liquid biopsy-guided therapy
- Marco Bonetti, Bernard Cole, Richard Gelber: Exploring treatment-effect heterogeneity using continuous biomarkers: the STEPP approach
- John Simes (University of Sydney) Design and analysis issues evaluating biomarkers in cancer clinical trials
- Panel Discussion
Track A
![](https://aaadv.org/wp-content/uploads/2022/07/jian-e1686887544917.jpg)
![](https://aaadv.org/wp-content/uploads/2023/07/Screenshot-2023-07-29-at-11.49.19-AM-e1695236970494.png)
![](https://aaadv.org/wp-content/uploads/2021/08/Laura-van-t-Veer.jpg)
![Jeanine Tie](https://aaadv.org/wp-content/uploads/2023/07/Screenshot-2023-07-29-at-11.50.45-AM.png)
![](https://aaadv.org/wp-content/uploads/2023/07/Screenshot-2023-07-29-at-11.53.31-AM-e1694788193549.png)
![](https://aaadv.org/wp-content/uploads/2023/09/sghosh.jpg)
11:00am (EST)
Session Chairperson: Jian Wang (AstraZeneca)
1:00pm (EST) Friday, September 15
Break
![](https://aaadv.org/wp-content/uploads/2021/07/2020_David_Arons_193.jpg)
![](https://aaadv.org/wp-content/uploads/2019/05/Chitkala-Kalidas-Ph.D..png)
![](https://aaadv.org/wp-content/uploads/2023/07/Screenshot-2023-07-28-at-3.45.24-PM.png)
![](https://aaadv.org/wp-content/uploads/2023/07/Screenshot-2023-07-28-at-3.46.40-PM.png)
![Kenneth Buetow](https://aaadv.org/wp-content/uploads/2022/07/Screen-Shot-2022-07-29-at-10.54.23-PM.png)
![Gregory Reaman](https://aaadv.org/wp-content/uploads/2023/07/Greg_V11.jpg)
1:30am (EST)
Satellite #3: Pediatric Neuroncology and Childhood Cancer Data Initiative
Session Chairperson: David Arons (National Brain Tumor Society)
- Chitkala Kalidas (Bayer): A global pediatric neuro oncololgy newwork
- Kristin Schroeder (Duke University): Tanzania and Duke pilot in global pediatric neuro-oncology
- Parvati Dev (Open Health Systems Laboratories): Information systems supporting a pediatric neuro-oncology
- Ken Buetow (Arizona State University) Digital Twin
- Greg Reaman (National Cancer Institute): Childhood Cancer Data Initiative
- Panel Discussion / QA
3:30pm (EST) Friday, September 15
End
Track B
![Terrell Baptiste](https://aaadv.org/wp-content/uploads/2022/07/Screen-Shot-2022-07-29-at-11.55.29-AM-e1686865521494.png)
![](https://aaadv.org/wp-content/uploads/2023/07/Screenshot-2023-07-29-at-1.17.28-PM.png)
![Barbara Bierer](https://aaadv.org/wp-content/uploads/2023/08/Screenshot-2023-08-02-at-2.23.47-PM-e1695051406726.png)
![](https://aaadv.org/wp-content/uploads/2023/09/Binita-Patel-scaled-e1694632912318.jpg)
![](https://aaadv.org/wp-content/uploads/2023/08/Screenshot-2023-08-02-at-2.25.50-PM-e1695051225116.png)
![](https://aaadv.org/wp-content/uploads/2019/05/Chitkala-Kalidas-Ph.D..png)
![Patricia Keegan](https://aaadv.org/wp-content/uploads/2022/07/Screen-Shot-2022-07-29-at-12.11.19-PM.png)
11:00am (EST)
Satellite #5 Panel: Use of Regulatory Headwinds to Manage Towards Properly Enrolled Clinical Trials
Session Chairperson: Terrel Baptiste (Gilead)
- Stacey Bledsoe (Gilead): Head of Clinical Trial Diversity, Gilead
- Binita Patel (Bayer): Clinical Operations, Diversity Lead, Bayer
- Barbara Bierer (MRCT Center): Center Director
- Shaalan Beg (Science37): Vice-President
- Panel Discussion
- Chitkala Kalidas (Bayer)– Invited Discussant
- Patricia Keegan (TopAllianceBio)– Invited Discussant
1:00pm (EST) Friday, September 15
Break
![](https://aaadv.org/wp-content/uploads/2023/07/Screenshot-2023-07-28-at-3.42.20-PM.png)
![](https://aaadv.org/wp-content/uploads/2023/09/Screenshot-2023-09-12-at-9.32.55-PM.png)
![](https://aaadv.org/wp-content/uploads/2023/07/Screenshot-2023-07-29-at-12.15.34-PM.png)
![](https://aaadv.org/wp-content/uploads/2023/07/Philip-E.-Castle-Ph.D.-M.P.H-e1689796578274.jpg)
![](https://aaadv.org/wp-content/uploads/2023/08/Screenshot-2023-08-07-at-2.55.15-PM.png)
![](https://aaadv.org/wp-content/uploads/2023/08/Screenshot-2023-08-17-at-3.25.06-PM.png)
![](https://aaadv.org/wp-content/uploads/2023/08/Screenshot-2023-08-17-at-3.32.44-PM-e1692890759812.png)
1:30pm (EST)
Satellite #6: Access to care following screening and prevention trials
Session Chairperson: Michelle Treagar (National Breast Cancer Coalition)
- Derek Raghavan (Levine Cancer Center): Screening for lung cancer
- Eduardo Vilar-Sanchez (MD Anderson): Lynch Syndrome Vaccines
- Panel Discussion
- Philip E. Castle (National Cancer Institute)- Invited Discussant
- Jeffrey Levi (George Washington University)– Invited Discussant
- Jennifer Berzock- Invited Discussant
- Christine Carpenter- Invited Discussant
3:30pm (EST) Friday, September 15
End
You will need to be an attendie form the event to access these resources available.